Table 2.
Baseline HOMA2-%B, HOMA2-%S, HOMA2-IR, and McA in the study subjects
| Parameters | HTG group (n = 118) |
NTG group (n = 73) |
Control group (n = 79) |
P for trend |
|---|---|---|---|---|
| HOMA2-%B | 93.47 ± 26.28a,b | 68.47 ± 21.29 | 79.92 ± 23.15 | <0.001 |
| HOMA2-%S | 48.40 (39.70, 68.70)a,b | 110.20 (62.55, 141.95) | 101.20 (79.90, 140.10) | <0.001 |
| HOMA2-IR | 2.09 (1.46, 2.52)a,b | 0.92 (0.70, 1.61) | 0.99 (0.71, 1.25) | <0.001 |
| McA | 5.05 ± 0.76a,b | 7.99 ± 1.79 | 8.34 ± 1.55 | <0.001 |
HTG group impaired glucose tolerance patients with hypertriglyceridemia, NTG group impaired glucose tolerance patients without hypertriglyceridemia; control group, control subjects; HOMA2-%B homeostasis model assessment index 2 for β-cell function, HOMA2-%S, homeostasis model assessment index 2 for insulin sensitivity, HOMA2-IR homeostasis model assessment index 2 for insulin resistance, McA McAuley index
a P < 0.017 (0.05 divided by the number of comparisons), significantly different compared with control group
b P < 0.017 (0.05 divided by the number of comparisons), significantly different compared with the NTG group